Exact Mass: 534.2438
Exact Mass Matches: 534.2438
Found 500 metabolites which its exact mass value is equals to given mass value 534.2438
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PA(2:0/20:3(8Z,11Z,14Z)-2OH(5,6))
PA(2:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0)
PA(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/2:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
N,N-bis[2-[(2-chlorobenzyl)-diethyl-ammonio]ethyl]oxalimidate
3beta,6alpha-dihydroxy-1alpha,7beta,11beta,15beta-tetraacetoxy-6,18-cyclo-ent-kaur-16-ene|nervonin A
4-N-Ac,4,6-O-Benzylidene-beta-D-4-Aminophenyl 2-acetamido-2-deoxyglucopyranoside
(3E,7E)-2alpha,10beta,13alpha,20-tetraacetoxy-5alpha-hydroxy-3,8-secotaxa-3,7,11-trien-9-one
(22SR,23SR,24RS,25SR)-12alpha,22:21,24-diepoxy-5alpha,6beta,12beta,17beta,25-pentahydroxy-1-oxo-with-2-en-26,23-olide|jaborosalactone 35
asterriquinone dimethyl ether
A member of the class of asterriquinones that is asterriquinone in which the hydrogens of both of the hydroxy groups have replaced by methyl groups.
2alpha,5alpha,7beta,13alpha-tetraacetoxy-10beta-hydroxyl-2(3->20)abeotaxan-9-one|2??,5??,7??,13??-Tetraacetoxy-10??-hydroxy-2(3鈥樏傗垎20)abeotaxan-9-one
(1R*,2R*,3S*,5Z,7S*,8S*,9S*,10S*,11Z,14S*,17R*)-2,14-diacetoxy-3-butyrloxy-8,17-epoxy-9-hydroxybriara-5,11-dien-18-one
(4beta,5beta,6alpha,18R,22R)-6-chloro-18,20-epoxy-4,5,22-trihydroxy-18-methoxy-1-oxoergost-2,24-dien-26-oic acid gamma-lactone|withaphysalin V
(3E,7E)-2alpha,5alpha,10beta,13alpha-tetraacetoxy-20-hydroxy-3,8-secotaxa-3,7,11-trien-9-one
(2E)-1-{2,4-dihydroxy-3-[(1R,2E,5S)-5-hydroxy-1,7-diphenylhept-2-en-1-yl]-6-methoxyphenyl}-3-phenylprop-2-en-1-one|katsumain B
Bulleyanin
C28H38O10_Methyl 5-acetoxy-6,10-dihydroxy-2,4b,7,7,10a,12a-hexamethyl-12-methylene-1,4,8-trioxohexadecahydro-2H-naphtho[1,2-h]isochromene-2-carboxylate
C28H38O10_1H-Pyrano[3,4:5,6]naphth[2,1-c]oxepin-3,8,11(9H)-trione, 5,12-bis(acetyloxy)dodecahydro-13-hydroxy-1,1,5a,7a,9,11b-hexamethyl-7-methylene
Ala Cys Arg Trp
Ala Cys Trp Arg
Ala Met Gln Trp
Ala Met Trp Gln
Ala Gln Met Trp
Ala Gln Trp Met
Ala Arg Cys Trp
Ala Arg Trp Cys
Ala Trp Cys Arg
Ala Trp Met Gln
Ala Trp Gln Met
Ala Trp Arg Cys
Cys Ala Arg Trp
Cys Ala Trp Arg
Cys Glu Lys Arg
Cys Glu Arg Lys
Cys His Ile Tyr
Cys His Leu Tyr
Cys His Tyr Ile
Cys His Tyr Leu
Cys Ile His Tyr
Cys Ile Asn Trp
Cys Ile Trp Asn
Cys Ile Tyr His
Cys Lys Glu Arg
Cys Lys Arg Glu
Cys Leu His Tyr
Cys Leu Asn Trp
Cys Leu Trp Asn
Cys Leu Tyr His
Cys Asn Ile Trp
Cys Asn Leu Trp
Cys Asn Trp Ile
Cys Asn Trp Leu
Cys Gln Val Trp
Cys Gln Trp Val
Cys Arg Ala Trp
Cys Arg Glu Lys
Cys Arg Lys Glu
Cys Arg Trp Ala
Cys Val Gln Trp
Cys Val Trp Gln
Cys Trp Ala Arg
Cys Trp Ile Asn
Cys Trp Leu Asn
Cys Trp Asn Ile
Cys Trp Asn Leu
Cys Trp Gln Val
Cys Trp Arg Ala
Cys Trp Val Gln
Cys Tyr His Ile
Cys Tyr His Leu
Cys Tyr Ile His
Cys Tyr Leu His
Asp Lys Ser Trp
Asp Lys Trp Ser
Asp Ser Lys Trp
Asp Ser Trp Lys
Asp Trp Lys Ser
Asp Trp Ser Lys
Glu Cys Lys Arg
Glu Cys Arg Lys
Glu His His Ile
Glu His His Leu
Glu His Ile His
Glu His Leu His
Glu Ile His His
Glu Lys Cys Arg
Glu Lys Met Gln
Glu Lys Gln Met
Glu Lys Arg Cys
Glu Leu His His
Glu Met Lys Gln
Glu Met Gln Lys
Glu Gln Lys Met
Glu Gln Met Lys
Glu Arg Cys Lys
Glu Arg Lys Cys
Phe His Met Thr
Phe His Thr Met
Phe Met His Thr
Phe Met Thr His
Phe Thr His Met
Phe Thr Met His
His Cys Ile Tyr
His Cys Tyr Ile
His Cys Tyr Leu
His Glu His Ile
His Glu His Leu
His Glu Ile His
His Glu Leu His
His Phe Met Thr
His Phe Thr Met
His His Glu Ile
His His Glu Leu
His His Ile Glu
His His Leu Glu
His His Asn Gln
His His Gln Asn
His Ile Cys Tyr
His Ile Glu His
His Ile His Glu
His Ile Tyr Cys
His Leu Cys Tyr
His Leu Glu His
His Leu His Glu
His Leu Tyr Cys
His Met Phe Thr
His Met Thr Phe
His Asn His Gln
His Asn Gln His
His Gln His Asn
His Gln Asn His
His Thr Phe Met
His Thr Met Phe
His Tyr Cys Ile
His Tyr Cys Leu
His Tyr Ile Cys
His Tyr Leu Cys
Ile Cys His Tyr
Ile Cys Asn Trp
Ile Cys Trp Asn
Ile Cys Tyr His
Ile Glu His His
Ile His Cys Tyr
Ile His Glu His
Ile His His Glu
Lys Cys Glu Arg
Lys Cys Arg Glu
Lys Asp Ser Trp
Lys Asp Trp Ser
Lys Glu Cys Arg
Lys Glu Met Gln
Lys Glu Gln Met
Lys Glu Arg Cys
Lys Met Glu Gln
Lys Met Gln Glu
Lys Gln Glu Met
Lys Gln Met Glu
Lys Arg Cys Glu
Lys Arg Glu Cys
Lys Ser Asp Trp
Lys Ser Trp Asp
Lys Trp Asp Ser
Lys Trp Ser Asp
Leu Glu His His
Leu His Glu His
Leu His His Glu
Met Glu Lys Gln
Met Glu Gln Lys
Met Lys Glu Gln
Met Lys Gln Glu
Met Gln Glu Lys
Met Gln Lys Glu
Met Gln Arg Thr
Met Gln Thr Arg
Met Arg Gln Thr
Met Arg Thr Gln
Met Thr Gln Arg
Met Thr Arg Gln
Asn His His Gln
Asn His Gln His
Asn Gln His His
Asn Trp Ile Cys
Pro Gln Gln Tyr
Pro Gln Tyr Gln
Pro Tyr Gln Gln
Gln Glu Lys Met
Gln Glu Met Lys
Gln His His Asn
Gln His Asn His
Gln Lys Glu Met
Gln Lys Met Glu
Gln Met Glu Lys
Gln Met Lys Glu
Gln Met Arg Thr
Gln Met Thr Arg
Gln Asn His His
Gln Pro Gln Tyr
Gln Pro Tyr Gln
Gln Gln Pro Tyr
Gln Gln Tyr Pro
Gln Arg Met Thr
Gln Arg Thr Met
Gln Thr Met Arg
Gln Thr Arg Met
Gln Thr Thr Trp
Gln Thr Trp Thr
Gln Trp Thr Thr
Gln Tyr Pro Gln
Gln Tyr Gln Pro
Arg Ala Cys Trp
Arg Ala Trp Cys
Arg Cys Ala Trp
Arg Cys Glu Lys
Arg Cys Lys Glu
Arg Cys Trp Ala
Arg Glu Cys Lys
Arg Glu Lys Cys
Arg Lys Cys Glu
Arg Lys Glu Cys
Arg Met Gln Thr
Arg Met Thr Gln
Arg Gln Met Thr
Arg Gln Thr Met
Arg Ser Ser Trp
Arg Ser Trp Ser
Arg Thr Met Gln
Arg Thr Gln Met
Arg Trp Ala Cys
Arg Trp Cys Ala
Arg Trp Ser Ser
Ser Asp Lys Trp
Ser Asp Trp Lys
Ser Lys Asp Trp
Ser Lys Trp Asp
Ser Arg Ser Trp
Ser Arg Trp Ser
Ser Ser Arg Trp
Ser Ser Trp Arg
Ser Trp Asp Lys
Ser Trp Lys Asp
Ser Trp Arg Ser
Ser Trp Ser Arg
Thr Phe Met His
Thr His Phe Met
Thr His Met Phe
Thr Met Phe His
Thr Met His Phe
Thr Met Gln Arg
Thr Met Arg Gln
Thr Gln Met Arg
Thr Gln Arg Met
Thr Gln Thr Trp
Thr Gln Trp Thr
Thr Arg Met Gln
Thr Arg Gln Met
Thr Thr Gln Trp
Thr Thr Trp Gln
Thr Trp Gln Thr
Thr Trp Thr Gln
Val Cys Gln Trp
Val Cys Trp Gln
Val Gln Cys Trp
Val Gln Trp Cys
Val Trp Cys Gln
Val Trp Gln Cys
Trp Ala Cys Arg
Trp Ala Met Gln
Trp Ala Gln Met
Trp Ala Arg Cys
Trp Cys Ala Arg
Trp Cys Ile Asn
Trp Cys Leu Asn
Trp Cys Asn Ile
Trp Cys Asn Leu
Trp Cys Gln Val
Trp Cys Arg Ala
Trp Cys Val Gln
Trp Asp Lys Ser
Trp Asp Ser Lys
Trp Ile Cys Asn
Trp Ile Asn Cys
Trp Lys Asp Ser
Trp Lys Ser Asp
Trp Leu Cys Asn
Trp Leu Asn Cys
Trp Met Ala Gln
Trp Met Gln Ala
Trp Asn Cys Ile
Trp Asn Cys Leu
Trp Asn Ile Cys
Trp Asn Leu Cys
Trp Gln Ala Met
Trp Gln Cys Val
Trp Gln Met Ala
Trp Gln Thr Thr
Trp Gln Val Cys
Trp Arg Ala Cys
Trp Arg Cys Ala
Trp Arg Ser Ser
Trp Ser Asp Lys
Trp Ser Lys Asp
Trp Ser Arg Ser
Trp Ser Ser Arg
Trp Thr Gln Thr
Trp Thr Thr Gln
Trp Val Cys Gln
Trp Val Gln Cys
Tyr Cys His Ile
Tyr Cys His Leu
Tyr Cys Ile His
Tyr Cys Leu His
Tyr His Cys Ile
Tyr His Cys Leu
Tyr His Ile Cys
Tyr His Leu Cys
Tyr Ile Cys His
Tyr Ile His Cys
Tyr Leu Cys His
Tyr Leu His Cys
Tyr Pro Gln Gln
Tyr Gln Pro Gln
Tyr Gln Gln Pro
(1R,2R)-N,N-Dihydroxy-N,N-bis(diphenylacetyl)cyclohexane-1,2-diamine
Methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate
(1S,2S)-N,N-Dihydroxy-N,N-bis(diphenylacetyl)cyclohexane-1,2-diamine
Emedastine difumarate
D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist D018926 - Anti-Allergic Agents
nickel(2+),2,7,12,17-tetraethyl-3,8,13,18-tetramethyl-1,4,5,10,11,14,15,20,21,23-decahydroporphyrin-22,24-diide
Acetamide, N-[3-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)propyl]-N-[4-[[3-(1,4-dihydro-2,4-dioxo-3(2H)-quinazolinyl)propyl]amino]butyl]-
D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C26170 - Protective Agent > C1509 - Neuroprotective Agent D020011 - Protective Agents Otaplimastat (SP-8203), a matrix metalloproteinase (MMP) inhibitor, blocks N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity in a competitive manner. Otaplimastat also exhibits anti-oxidant activity. Otaplimastat can be used for the research of brain ischemic injury[1][2][3].
1-(2-Ethoxyethyl)-2-(4-methylhexahydro-1H-1,4-diazepin-1-yl)benzimidazole fumarate (1:2)
(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[3-[(8S,9R,10S,13R,14R,17S)-17-hydroxy-10,13-dimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoyloxy]oxane-2-carboxylic acid
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-propanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
(6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
(1r,3s,4s,5r,7s,8r,9s,10z,12s,13s,14s)-4,8,9-tris(acetyloxy)-3,6,6,10,14-pentamethyl-2-oxo-16-oxatetracyclo[10.3.1.0¹,¹².0⁵,⁷]hexadec-10-en-13-yl acetate
(4r,11s,14s,17s)-4-[(2s)-butan-2-yl]-14-[(1r)-1-hydroxyethyl]-17-isopropyl-11-methyl-19-oxa-6-thia-3,10,13,16,21,22-hexaazatricyclo[16.2.1.1⁵,⁸]docosa-1(20),2,5(22),7,9,12,15,18(21)-octaene-2,9,12,15-tetrol
(1e,3s,4s,6s,9r,11s,12s,14s)-3,9,12-tris(acetyloxy)-14-hydroxy-7,11,16,16-tetramethyl-10-oxotricyclo[9.3.1.1⁴,⁸]hexadeca-1,7-dien-6-yl acetate
4,8,9-tris(acetyloxy)-3,6,6,10,14-pentamethyl-2-oxo-16-oxatetracyclo[10.3.1.0¹,¹².0⁵,⁷]hexadec-10-en-13-yl acetate
3-amino-2-hydroxy-n-[(6s,7r)-7,10,10-trimethyl-12-(2-methylpropyl)-2,5,9,11-tetraoxo-3-(sec-butyl)-1,4,8-trioxacyclododecan-6-yl]benzenecarboximidic acid
(2e,4e,6e)-n-{5-hydroxy-5-[(1e,3e,5e)-6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)-c-hydroxycarbonimidoyl]hexa-1,3,5-trien-1-yl]-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl}-10-methylundeca-2,4,6-trienimidic acid
n-[7-(butanoyloxy)-8-hexyl-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-3-yl]-2-hydroxy-3-[(hydroxymethylidene)amino]benzenecarboximidic acid
(3r,4r,5s,7s,10s,11r,13s)-7,10,13-tris(acetyloxy)-3-hydroxy-4,14,15,15-tetramethyl-2-oxotricyclo[9.3.1.1⁴,⁸]hexadeca-1(14),8-dien-5-yl acetate
(1r,2r,3r,4r,6s,8s,9r,10s,11s,13r)-2,3,8-tris(acetyloxy)-6-hydroxy-5,5,9-trimethyl-14-methylidene-15-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-11-yl acetate
[2,10,13-tris(acetyloxy)-5-hydroxy-8,12,15,15-tetramethyl-9-oxobicyclo[9.3.1]pentadeca-3,7,11-trien-4-yl]methyl acetate
14-hydroxy-5-(hydroxymethyl)-6,6,21,21-tetramethyl-3,7,18,23-tetraazaoctacyclo[16.13.0.0³,¹⁶.0⁴,⁷.0⁴,¹⁴.0⁸,¹³.0²²,³⁰.0²⁴,²⁹]hentriaconta-1(31),8,10,12,15,19,22(30),24,26,28-decaene-2,17-dione
2,5-dimethoxy-3-[2-(2-methylbut-3-en-2-yl)-1h-indol-3-yl]-6-[1-(2-methylbut-3-en-2-yl)indol-3-yl]cyclohexa-2,5-diene-1,4-dione
(1s,2s,3r,5s,7r,8s,9s,10s,11r,15s)-3,10,15-tris(acetyloxy)-9-hydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.1⁵,⁸.0¹,¹¹.0²,⁸]octadecan-7-yl acetate
(1r,2r,3r,5s,7s,8s,9r,10r)-2,9,10-tris(acetyloxy)-5-hydroxy-8,12,15,15-tetramethyl-4-methylidene-13-oxotricyclo[9.3.1.0³,⁸]pentadec-11-en-7-yl acetate
6,7',11'-tris(acetyloxy)-3,3-dimethyl-10'-methylidene-2'-oxo-3'-oxaspiro[cyclohexane-1,5'-tricyclo[7.2.1.0¹,⁶]dodecan]-2-ylmethyl acetate
2α,5α,7β,13α-tetraacetoxy-10β-hydroxy-2(3→20)abeotaxan-9-one
{"Ingredient_id": "HBIN005246","Ingredient_name": "2\u03b1,5\u03b1,7\u03b2,13\u03b1-tetraacetoxy-10\u03b2-hydroxy-2(3\u219220)abeotaxan-9-one","Alias": "NA","Ingredient_formula": "C28H38O10","Ingredient_Smile": "CC1=C2C(C(=O)C3(CC(=CC(C(C2(C)C)CC1OC(=O)C)OC(=O)C)C(CC3OC(=O)C)OC(=O)C)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21013","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}